Those of you who have read The Stock Market is For Everyone, and/or regularly follow this blog, might be wondering right about now, “Has Eric been hacked?!” after seeing the title of this post. Not to worry! It’s still me. Read on…
On November 2, 2018, Illumina (NASDAQ: ILMN), the gene-sequencing giant, announced that it would be acquiring its much smaller competitor, Pacific Biosciences of California (NASDAQ: PACB) for $1.2 billion in cash, or $8 a share. The deal is expected to close in mid-2019.
Currently, PACB is at $7.52, which is 6% below the deal price. The reason it’s trading below the deal price is that the acquisition is not expected to close for at least five to six months.
The likelihood that this deal would fall apart is slim to none.
Therefore, if you have money sitting around that you can tie up for six months, this opportunity guarantees that you’ll get a return somewhere between 5 and 6% depending on where you buy it.
In my opinion it’s worth it, if you have the money and the time to wait.
Disclaimer/Disclosure Statement: Information in this article is not intended to be a recommendation to invest in any stock. Rather, it is presented for readers’ education and consideration when making their own investment decisions. The author has no position in either of the two companies mentioned.
Click the image of the book at left to be taken to its Amazon page. (Disclosure: As a participant in the Amazon Services LLC Associates Program, I earn a small commission on each sale generated through these links.)